07/2019 - Interview on epigenetic softdrugs and prodrugs
Interview of M. Jung with Oxford Global about epigenetic softdrugs and prodrugs: Q&A Session with Manfred Jung.
06/2019 - LSD1 inhibitors in the spotlight
Our collaboration on LSD1 inhibitors with the Lübbert and Schüle groups highlighted by the DKFZ magazine: Alter Wirkstoff, neuer Nutzen.
05/2017 - New grant on sirtuins
The DFG is funding a new collaborative project (together with W. Sippl, Halle) on Isotype selective sirtuin inhibitors.
12/2016 - Video of Epigenetics Lecture
The Freiburg Institute for Advanced Studies (FRIAS) has released the video of an Epigenetics Lecture by A. Ganesan.
The lecture was part of the FRIAS Lunch Lecture series "Ignorance - what we don't know".
11/2016 - Surprising Science video on epigenetics
The research portal Surprising Science of the University of Freiburg has released a video on epigenetic research in our group and the CRC 992 Medical Epigenetics.
10/2016 - Phoenix Pharmazie Wissenschaftspreis for Manfred Jung
The Phoenix group has awarded the 2016 Phoenix Pharmazie
Wissenschaftspreis to our group in the category Pharmaceutical Chemistry. Basis for the prize is our publication "Selective Sirt2 inhibition by ligand-induced
rearrangement of the active site" (Rumpf et al., Nat. Commun. 6 (2015) 6263).
(Pressemitteilung der Uni Freiburg)
5/2016 - Renewal for CRC 992 Medical Epigenetics
The CRC 992 Medical Epigenetics (MEDEP, Speaker: R. Schüle)
has been renewed for another four years by the Deutsche
Forschungsgemeinschaft (DFG). The Jung group receives funding for a project on methyllysine reader proteins and their inhibitors.
4/2016 - 3rd Freiburg Epigenetics Spring Meeting
The 3rd Freiburg Epigenetics Spring Meeting took place from April 10th to 13th. It was organzied by the FRIAS (Freiburg Institute of Advanced Studies) Project Group "Chemical
Epigenetics" (B. Breit, O. Einsle, S. Günther, M. Jung) and the CRC 992 Medical Epigenetics (R. Schüle). A detailed
report is available here.
2/2016 - Press release on our paper on Spindlin1 inhibitors (in German)
2015 - Press release on our paper on new sirtuin inhibitors and their structure in complex with Sirt2 (in German)
2014 - New COST Action Epigenetic Chemical Biology
The EU COST program is funding a new initative on Epigenetic Chemical Biology (EPICHEM, Action CM 1406). The key objective of the Action is to establish the first
European chemical biology network focused on epigenetics. It will provide common ground for researchers from academia, research institutes, SMEs and multinational organizations.
The fruitful interactions between these sectors will lead to the creation of new chemical tools as well as leads for therapeutics and agrochemicals.
The Action's further objective is to increase awareness of epigenetics within the European scientific community and it will provide training for ESRs and emphasize inclusiveness
by COST priority member countries. M. Jung and C. Gerhäuser (DKFZ) have been appointed as German Management Committee Members. Link to press release
2014 - New DFG-funded project on HDAC8/10 inhibitors
The Deutsche Forschungsgemeinschaft (DFG) is funding a new joint project of the Jung group together with W. Sippl (Halle), I. Oehme and O. Witt (both Heidelberg)
on the optimization of inhibitors of the histone deacetylase (HDAC) subtypes 8 and 10. Both HDAC8 and 10 have not received so much attention with regard to drug discovery, but
have been identified as potential targets in neuroblastoma. Bioguided optimization of available lead structures should lead to potent and selective inhibitors for probing
the biology of these HDACs to further dissect their role as drug targets.
2014 - New project within Research Training Group on cofactors
A new Research training group (Graduiertenkolleg, RTG1976, Speaker A. Bechthold) on "Functional diversity of cofactors in Enzymes" has been
funded by the German Science Foundation (DFG). The Jung group will work on the NAD-dependent histone deacetylase smSirt2 from Schistosoma mansoni. For more info see
2014 - Eva-Maria Herrlinger wins UniDAZ Science Prize for her Bachelor Thesis
During this year's Interpharm meeting in Berlin, our student Eva-Maria Herrlinger was awarded the UniDAZ Science Prize for her Bachelor Thesis. Eva studied the structure-activity relationship of novel
inhibitors of histone demethylases and deacetylases, which she had synthesized and tested during her Bachelor Thesis project in the Jung group. After obtaining her B. Sc. degree, she has
rejoined the group as a student research assistant.
2013 - New EU consortium on Epigenetic anti-parasite drugs
Within the framework of FP-7, the consortium A-PARADDISE (Anti-parasitic drug discovery in epigenetics) will unite 16 groups from five countries to discover new drugs against
the major parasites Schistosoma, Plasmodium, Leishmania and Trypanosma using the epigenetic machinery of these pathogens. A-PARADDISE website.
German press release.
2013 - DPhG Annual Meeting in Freiburg
The annual meeting of the German Pharmaceutical Society (DPhG) will take place in Freiburg im Breisgau from October 9th through 11th, 2013. The organizing committee is headed by
the chairman of the DPhG local group, Manfred Jung.
2013 - SFB 992 Homepage Launched
The official webpage for the recently established Collaborative Research Center 992 Medical Epigenetics (MEDEP) has been launched. You can find further information
on the research projects studied as well as the people involved in this consortium on www.sfb992.uni-freiburg.de.
2012 - M. Jung in Science Webinar on Epigenetic Drug Discovery
This webinar presents an introduction into Epigenetics, an overview over
different assay formats for screening and case studies.
2012 - M. Jung Member of the Editorial Board of the Journal of Biomolecular Screening
M. Jung is a member of the Editorial Board of the Journal of Biomolecular Screening (JBS). JBS is a leading peer-reviewed journal
focusing on drug discovery sciences. It publishes information that enables researchers to evaluate current technologies and incorporate
applications to enhance performance and objectives.
2012 - M. Jung receives funding in the German Consortium for Translational Cancer Research
This initiative (Deutsches Konsortium für Translationale Krebsforschung - DKTK) will build up and support
translational research units across Germany. Epigenetic drug discovery is one of the research programs
within DKTK and the Jung group will be funded from this program.
2012 - M. Jung interviewed on Epigenetics
Manfred Jung was an invited speaker at the COST Conference on Personalized
Medicine (Larnaca, Cyprus, 17.-22.06.12) and was interviewed on
Epigenetics (see video on YouTube).
2012 - Author Profile of Manfred Jung in ChemMedChem
Featured author in ChemMedChem
2012 - New Collaborative Reserach Centre: SFB 992 Medical Epigenetics (MEDEP)
The German research foundation will fund a new colloborative reserach center for Medical Epigenetics in Freiburg. The project is headed by
Roland Schüle and will focus on the analysis of epigenetic regulation
from basic understanding to animal models and clinical settings. These
findings will be translated into new diagnostic tools and used for the
development of new epigenetic inhibitors. M. Jung is a prinicipal
investigator in MEDEP and the coordinator of the Integrated Research
(Press releases University)
2011 - M. Jung receives finding in KFO 201
Funding for the clinical research unit
»Polycystic Kidney Disease - from
Model Organisms to Novel Therapies« (KFO 201) has been extended by the
Deutsche Forschungsgemeinschaft for three more years. M. Jung has joined
now this group as a principal investigator in a joint project
(Regulation of ciliogenesis and ciliary disassembly by nephrocystins)
with Prof. G. Walz (Nephrology, University Freiburg Medical Centre) to
search for new potential drugs for the treatment of polycystic kidney
2011 - M. Jung named as Academic Editor for PLoS One
Manfred Jung served (2011-2014) as an Academic Editor for PLoS ONE.
PLoS ONE is a peer-reviewed open-access journal that features reports
of original research from disciplines in science and medicine.
2011 - "Structure based epigenetic drug discovery" elected as FRIAS interdisciplinary research group.
The application of Professors O. Einsle (Organic Chemistry and
Biochemistry), Prof. Jung and Prof. Sippl (Medicinal Chemistry,
University of Halle) on structure based epigenetic drug discovery has
been elected by the FRIAS (Freiburg Institute for Advanced Studies) as
an Interdisciplinary research group for 2011/12.
2010 - Prof. Jung receives funding in priority program "Epigenetic regulation of normal hematopoiesis and its dysregulation in myeloid neoplasia" (SPP 1463)
(SPP 1463 Homepage, DFG entry)
2010 - Most accessed article in ChemMedChem 7/2009-6/2010 - Most cited in 2009/2010
Strategies towards inhibitors of histone methyltransferases and demethylases. A. Spannhoff, A.-T. Hauser, R. Heinke, W. Sippl, M. Jung; ChemMedChem.
4 (2009) 1568-1582. This review deals with the involvement of histone methyltransferases and demethylases in human disease and presents an overview over the available inhibitors.
2010 - MedChemWatch: Young Researcher
Presentation of our research profile
2010 - New COST action "Epigenetics - from bench to bedside"
The objective of this Action is to unite synthetic chemists and chemical
biologists working in epigenetics, and attract new researchers to the
area. The Action will create a pan-European framework for networking and
research collaborations in epigenetics. It will feature a unique
crossdisciplinary approach that brings together chemists, biologists,
pharmacologists and clinicians. This will enable a focus on both
innovative and translational science that targets grand challenges
within this area. The Action will feature participation from academia,
multinational pharmaceutical companies and small to medium enterprises.
2010 - 3sat: scobel - Neues über Krebs
Mit Manfred Jung, Otmar Wiestler (Vorsitzender des Stiftungsvorstandes des Deutschen Krebsforschungszentrums) und Susanne Vössing (Sterneköchin und Expertin für angepasste Ernährung für Patienten in onkologischer Behandlung)
2009 - FP7 project approved: SEtTReND
SEtTReND is a collaborative EU-project (FP7-HEALTH-2009-single-stage)
that will deal with identification of epigenetic drug targets in the
pathogen Schistosoma mansoni and the discovery of small molecule
inhibitors of these enzymes that may serve as new future antiparasital
2009 - Scientific advisor for FP6 project: SMARTER Chromatin
M. Jung has been appointed as scientific advisor to the EU FP6 program
"SMARTER Chromatin". The SMARTER Network consists of four research
groups with high expertise in chromatin research and Chroma
Therapeutics, a company focused on the generation of cancer and
inflammation treatments. The SMARTER project aims at the development and
improvement of compounds targeting epigenetic regulators.
2009 - Book: "Epigenetic Targets in Drug Discovery" released
This reference edited by W. Sippl and M. Jung covers everything a drug
researcher needs to know about targeting epigenetic mechanisms of
disease. The book is divided into sections on methodology (such as
molecular modelling, chromatin immunoprecipitation - ChIP or screening
assays) and chapters on epigenetic enzymes as drug targets and available
Übersichtsartikel zum Thema Epigenetik
In diesem Artikel wird eine allgemeine Einführung in das Thema
Epigenetik und die auf diesem Gebiet bereits zugelassenen Arzneistoffe
gegeben. Die Literaturliste zu diesem Artikel finden Sie hier.